Nuvalent, Inc.
- NUVL
- NASDAQ
- Biotechnology
- Targeted Cancer Therapies
- ROS1 Inhibitors
$123.96
Quote Jul 15, 2026, 01:30 PM UTC
+0.43%over the last month
Max drawdown −0.1%From 1-month high 0.0%3 months +14.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$9.13B
Quote Jul 15
Next earnings
—
Data unavailable
Analyst target
$127.32
+2.7% from here
Floor
$123.72
0.2% below price
Where the price sits
19 analysts
Analyst range, low to high
$122.85$165.00
- Price $123.96
- Resistance $124.01
- Consensus $127.32
The price is just above its floor and right under resistance. Analysts' average target sits about 3% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NUVLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
234